AUS
NZ
UK
CA
USA
IND
Highlights
- Sonic Healthcare (SHL) to acquire Laboratory Group Dr. Kramer & Colleagues in Germany.
- Deal valued at €423 million, combining cash payment and share issuance.
- Acquisition strengthens Sonic's footprint in Germany and Europe.
Sonic Healthcare (ASX:SHL), a global leader in medical diagnostics, is set to expand its presence in Europe with the acquisition of Laboratory Group Dr. Kramer & Colleagues (LADR), one of Germany’s leading medical laboratory networks. LADR is recognized among the country’s top five medical laboratory groups, with a wide-reaching network of standalone and hospital-based laboratories.
The acquisition agreement values LADR at €423 million, on a cash- and debt-free enterprise value basis. Sonic will pay a portion of this value through the issuance of ordinary shares, capped at €222 million, with the remainder settled in cash. The transaction signifies Sonic's growing commitment to expanding its European footprint while leveraging LADR’s established reputation and operational capabilities.
LADR, founded in 1945 by the Kramer family, is now led by its third generation. The group employs over 2,800 full-time staff across its facilities, with its central laboratory located in Geesthacht, near Hamburg. LADR also maintains a strategic presence in Poland, further enhancing its regional influence. Its extensive network and specialized medical expertise complement Sonic’s vision of delivering high-quality diagnostic services worldwide.
The financial and operational strength of LADR underscores the value of the acquisition. The group is projected to achieve revenue of approximately €370 million in 2024, equivalent to about A$610 million. Both organizations anticipate strong synergies in procurement, laboratory operations, logistics, equipment maintenance, and distribution of medical consumables, driving significant efficiency improvements.
Cultural and operational alignment between LADR and Sonic is a cornerstone of this partnership. Key executives from LADR, including Prof. Jan Kramer (CEO and Medical Director), Dr. Tobias Kramer (Medical Director – Infection Prevention and Control), and Mr. Thomas Wolff (CFO), will remain actively involved under long-term agreements. Their expertise is expected to play a pivotal role in seamlessly integrating the operations of the two organizations.
This acquisition reinforces Sonic’s strategic focus on growth and innovation in the medical diagnostics sector while consolidating its market position in Europe. With LADR’s established network and Sonic’s global expertise, this partnership is poised to deliver significant advancements in diagnostic services across the region.
